ResGen IPO Review & Recommendations

ResGen IPO Review by Dilip Davda May apply

[Dilip Davda]  The company started its commercial production from 2021-22 only and results for the sub-period of FY23 raise eyebrows. The sustainability of margins reported is a major concern and it is operating in a high-risk segment that also has the impact of government policies. The segment is highly competitive with many private local players around. The large equity base in the context of its current working too poses concern. Considering its aggressive pricing and the likely challenges for future prospects, well-informed/cash surplus investors may consider investing for the long-term, while others may skip. Read detail review...